Why the study?
Does a higher-dose heparin protocol targeting whole blood concentration reduce postoperative bleeding compared to a standard ACT-guided protocol in adult patients undergoing cardiopulmonary bypass?
Does a higher-dose heparin protocol targeting whole blood concentration reduce postoperative bleeding compared to a standard ACT-guided protocol in adult patients undergoing cardiopulmonary bypass?
A higher-dose heparin protocol targeting whole blood concentration does not significantly alter postoperative bleeding or transfusion requirements compared to a standard ACT-guided protocol in patients undergoing cardiopulmonary bypass.
Standard ACT-guided heparin dosing remains appropriate; confirms no bleeding or transfusion benefit from higher whole-blood concentration targets in cardiopulmonary bypass.
A group of 63 adult patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass (CPB) were studied to examine the relationship between heparin doses administered and postoperative bleeding. Patients were randomly assigned either to receive heparin 200 U/kg and additional heparin as needed to reach and maintain an activated clotting time (ACT) greater than 400 s for CPB (group A, n = 30), or to receive heparin 400 U/kg and additional heparin as needed to reach and maintain a whole blood heparin concentration greater than 4.0 U/ml for CPB (group H, n = 33). Groups were compared for the amount of postoperative bleeding, heparin rebound, homologous transfusion requirements, and standard laboratory coagulation tests. In the last 33 patients studied, additional tests of platelet aggregation and plasma levels of beta thromboglobulin (BTG), antithrombin III, and several markers of fibrinolysis were measured and compared by group. The mean heparin dose was 28,000 +/- 4,800 U for group A and 57,000 +/- 10,700 U for group H (P less than 0.05 for group A vs. group H). At 8 and 24 h postoperatively, mediastinal drainage did not differ significantly between groups (mean 24-h drainage +/- SD = 901 +/- 414 ml in group A, 1035 +/- 501 ml in group H), nor did the incidence of transfusion with homologous blood products.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Gravlee et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: